Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 5 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9981944

    GDF-8 inhibitors

    Rigel Pharmaceuticals, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted
  2. US 9920041

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted
  3. US 9913842

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  4. US 9913843

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  5. US 9890144

    Compounds and method for treating autoimmune diseases

    Rigel Pharmaceuticals, Inc. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  6. US 9884868

    TGF-beta inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  7. US 9878992

    GDF-8 inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jan 30, 2018 · Expires Jan 25, 2038

    granted
  8. US 9845311

    Nrf2 activating compounds and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Dec 19, 2017 · Expires Dec 14, 2037

    granted
  9. US 9845512

    Screening assay employing Dex and GDF8

    Rigel Pharmaceuticals, Inc. · Granted Dec 19, 2017 · Expires Dec 14, 2037

    granted
  10. US 9834568

    Kinase inhibitors and their uses

    Rigel Pharmaceuticals, Inc. · Granted Dec 5, 2017 · Expires Nov 30, 2037

    granted
  11. US 9751893

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Sep 5, 2017 · Expires Aug 31, 2037

    granted
  12. US 9737554

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  13. US 9732073

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  14. US 9732070

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  15. US 9730930

    Treatment for vitiligo

    Rigel Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  16. US 9725419

    Cycloalkyl substituted pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  17. US 9701647

    Tetrazolones as a carboxylic acid bioisosteres

    Rigel Pharmaceuticals, Inc. · Granted Jul 11, 2017 · Expires Jul 6, 2037

    granted
  18. US 9682976

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  19. US 9663496

    AMPK-activating heterocyclic compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  20. US 9650391

    N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted May 16, 2017 · Expires May 11, 2037

    granted
  21. US 9644224

    Methods for cyclizing synthetic polymers

    Rigel Pharmaceuticals, Inc. · Granted May 9, 2017 · Expires May 4, 2037

    granted
  22. US 9624229

    Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

    Rigel Pharmaceuticals, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  23. US 9611260

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted
  24. US 9598432

    2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

    Rigel Pharmaceuticals, Inc. · Granted Mar 21, 2017 · Expires Mar 16, 2037

    granted